clinical trials

Helping Cancer Patients Navigate Clinical Trials
Helping Cancer Patients Navigate Clinical Trials
BioSpace
clinical trials
patients
cancer
Flag link:
Forbius completes enrollment into phase 1a solid tumour trial of AVID200
Forbius completes enrollment into phase 1a solid tumour trial of AVID200
Pharmaceutical Business Review
Forbius
fibrosis
cancer
AVID200
solid tumors
clinical trials
Flag link:
Reata shocks analysts with pivotal win in Friedreich's ataxia
Reata shocks analysts with pivotal win in Friedreich's ataxia
Fierce Biotech
Reata Pharmaceuticals
omaveloxolone
Friedreich's Ataxia
clinical trials
Flag link:
Staying Ahead of Biosimilar Competition, Roche's Rituxan Shows Superiority in Rare Autoimmune Skin Disease
Staying Ahead of Biosimilar Competition, Roche's Rituxan Shows Superiority in Rare Autoimmune Skin Disease
BioSpace
Roche
clinical trials
Rituxan/MabThera
MMF
pemphigus vulgaris
Flag link:
Pfizer posts detailed phase 3 data on its Dupixent rival
Pfizer posts detailed phase 3 data on its Dupixent rival
Fierce Biotech
Pfizer
clinical trials
atopic dermatitis
abrocitinib
Dupixent
Sanofi
Regeneron
Flag link:
Gilead, Galapagos share 52-week update on filgotinib
Gilead, Galapagos share 52-week update on filgotinib
Fierce Biotech
Gilead Sciences
Galapagos
filgotinib
clinical trials
rheumatoid arthritis
Flag link:
Alexion bags option on Stealth's phase 3 rare disease drug
Alexion bags option on Stealth's phase 3 rare disease drug
Fierce Biotech
Alexion
Stealth BioTherapeutics
clinical trials
mitochondrial myopathy
elamipretide
Flag link:
Researchers Find 15% of Trials Could be Replicated Using Real World Data
Researchers Find 15% of Trials Could be Replicated Using Real World Data
RAPS.org
clinical trials
RWD
RWE
real world data
Flag link:
Novartis' ligelizumab outperforms Roche's Xolair in chronic urticaria clearance
Novartis' ligelizumab outperforms Roche's Xolair in chronic urticaria clearance
Pharmafile
Novartis
clinical trials
ligelizumab
Roche
Xolair
chronic urticaria
Flag link:
Partner Bayer pushes Ionis' antithrombotic drug into mid-stage development
Partner Bayer pushes Ionis' antithrombotic drug into mid-stage development
Endpoints
Bayer
Ionis Pharmaceuticals
Factor XI
anti-thrombotics
clinical trials
IONIS-FXI-LR
Flag link:
Rare Disease Clinical Trials: FDA Awards $15M in Grants
Rare Disease Clinical Trials: FDA Awards $15M in Grants
RAPS.org
grants
clinical trials
FDA
Rare Diseases
Flag link:
Here's Why Seattle Genetics Climbed 17.6% in September
Here's Why Seattle Genetics Climbed 17.6% in September
Motley Fool
Seattle Genetics
ESMO
clinical trials
tucatinib
colorectal cancer
enfortumab vedotin
urothelial cancer
Flag link:
Early readout from small NGM study shows NASH drug hits liver fat, but shares fall
Early readout from small NGM study shows NASH drug hits liver fat, but shares fall
Fierce Biotech
NGM Biopharmaceuticals
NASH
clinical trials
FGF19 aldafermin
Flag link:
Two acute cases of liver disease in healthy subjects kill Arbutus' hep B program
Two acute cases of liver disease in healthy subjects kill Arbutus' hep B program
Endpoints
Arbutus BioPharma
hepatitis B
clinical trials
Vivek Ramaswamy
AB-506
Flag link:
The Medicines Company Surges on Positive Drug Trial Results
The Medicines Company Surges on Positive Drug Trial Results
Motley Fool
Medicines Company
inclisiran
clinical trials
Flag link:
Boston Scientific’s Shining Moment at TCT
Boston Scientific’s Shining Moment at TCT
Medical Devices and Diagnostics Industry
Boston Scientific
FDA
clinical trials
TCT
Synergy Bioabsorbable Polymer stent
Flag link:
Seattle Genetics makes case it can be more than Adcetris
Seattle Genetics makes case it can be more than Adcetris
Biopharma Dive
Seattle Genetics
Adcetris
clinical trials
ESMO
enfortumab vedotin
Astellas
tucatinib
Flag link:
Reeling from a hefty civil and criminal settlement, Avanir stumbles into PhIII Alzheimer's failure
Reeling from a hefty civil and criminal settlement, Avanir stumbles into PhIII Alzheimer's failure
Endpoints
Avanir
Alzheimer's disease
clinical trials
Nuedexta
Flag link:
Novartis announces positive results from asthma combinations
Novartis announces positive results from asthma combinations
Pharmaforum
Novartis
asthma
QMF149
QVM149
clinical trials
Flag link:
Samsung Bioepis announces phase 3 results of SB8, Bevacizumab biosimilar candidate, at ESMO 2019 Congress
Samsung Bioepis announces phase 3 results of SB8, Bevacizumab biosimilar candidate, at ESMO 2019 Congress
Pharmaceutical Business Review
ESMO
Samsung Bioepis
clinical trials
SB8
biosimilars
bevacizumab
non-small cell lung cancer
Flag link:

Pages